Lexicon Fixed Asset Turnover from 2010 to 2024

LXRX Stock  USD 0.80  0.02  2.44%   
Lexicon Pharmaceuticals Fixed Asset Turnover yearly trend continues to be fairly stable with very little volatility. Fixed Asset Turnover will likely drop to 0.15 in 2024. During the period from 2010 to 2024, Lexicon Pharmaceuticals Fixed Asset Turnover regression line of annual values had r-squared of  0.03 and arithmetic mean of  9.75. View All Fundamentals
 
Fixed Asset Turnover  
First Reported
2010-12-31
Previous Quarter
0.16029823
Current Value
0.15
Quarterly Volatility
21.15086075
 
Credit Downgrade
 
Yuan Drop
 
Covid
Check Lexicon Pharmaceuticals financial statements over time to gain insight into future company performance. You can evaluate financial statements to find patterns among Lexicon Pharmaceuticals' main balance sheet or income statement drivers, such as Depreciation And Amortization of 526.3 K, Interest Expense of 13.8 M or Total Revenue of 1.1 M, as well as many indicators such as Price To Sales Ratio of 209, Dividend Yield of 0.0 or PTB Ratio of 5.52. Lexicon financial statements analysis is a perfect complement when working with Lexicon Pharmaceuticals Valuation or Volatility modules.
  
Check out the analysis of Lexicon Pharmaceuticals Correlation against competitors.
For more information on how to buy Lexicon Stock please use our How to Invest in Lexicon Pharmaceuticals guide.

Latest Lexicon Pharmaceuticals' Fixed Asset Turnover Growth Pattern

Below is the plot of the Fixed Asset Turnover of Lexicon Pharmaceuticals over the last few years. It is Lexicon Pharmaceuticals' Fixed Asset Turnover historical data analysis aims to capture in quantitative terms the overall pattern of either growth or decline in Lexicon Pharmaceuticals' overall financial position and show how it may be relating to other accounts over time.
Fixed Asset Turnover10 Years Trend
Pretty Stable
   Fixed Asset Turnover   
       Timeline  

Lexicon Fixed Asset Turnover Regression Statistics

Arithmetic Mean9.75
Geometric Mean0.91
Coefficient Of Variation217.02
Mean Deviation12.83
Median0.50
Standard Deviation21.15
Sample Variance447.36
Range81.3134
R-Value0.16
Mean Square Error469.29
R-Squared0.03
Significance0.57
Slope0.76
Total Sum of Squares6,263

Lexicon Fixed Asset Turnover History

2024 0.15
2023 0.16
2022 0.0671
2021 0.25
2020 81.34
2019 22.93
2018 3.98

About Lexicon Pharmaceuticals Financial Statements

Lexicon Pharmaceuticals investors use historical fundamental indicators, such as Lexicon Pharmaceuticals' Fixed Asset Turnover, to determine how well the company is positioned to perform in the future. Understanding over-time patterns can help investors decide on long-term investments in Lexicon Pharmaceuticals. Please read more on our technical analysis and fundamental analysis pages.
Last ReportedProjected for Next Year
Fixed Asset Turnover 0.16  0.15 

Also Currently Popular

Analyzing currently trending equities could be an opportunity to develop a better portfolio based on different market momentums that they can trigger. Utilizing the top trending stocks is also useful when creating a market-neutral strategy or pair trading technique involving a short or a long position in a currently trending equity.

Additional Tools for Lexicon Stock Analysis

When running Lexicon Pharmaceuticals' price analysis, check to measure Lexicon Pharmaceuticals' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Lexicon Pharmaceuticals is operating at the current time. Most of Lexicon Pharmaceuticals' value examination focuses on studying past and present price action to predict the probability of Lexicon Pharmaceuticals' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Lexicon Pharmaceuticals' price. Additionally, you may evaluate how the addition of Lexicon Pharmaceuticals to your portfolios can decrease your overall portfolio volatility.